NCT00049166View on ClinicalTrials.gov

Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

July 31, 2007

Conditions
Stage II Squamous Cell Carcinoma of the Lip and Oral CavityStage II Squamous Cell Carcinoma of the OropharynxStage III Squamous Cell Carcinoma of the Lip and Oral CavityStage III Squamous Cell Carcinoma of the OropharynxStage IV Squamous Cell Carcinoma of the Lip and Oral CavityStage IV Squamous Cell Carcinoma of the Oropharynx
Interventions
DRUG

erlotinib hydrochloride

Given orally

DRUG

cisplatin

Given IV

RADIATION

intensity-modulated radiation therapy

Undergo intensity modulated radiation therapy

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

21287-8936

Johns Hopkins University, Baltimore

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00049166 - Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer | Biotech Hunter | Biotech Hunter